ALPI

Logistics Provider ALPI Portugal Selects BIO-key for Secure Data Access, Including Multi-factor Authentication and Single Sign-On, Both Internally and for B2B

Retrieved on: 
Friday, October 27, 2023
Single, Multi, Dominican Republic, International, MFA, Workforce, Single sign-on, Radio, SSO, IAM, Altice, Altice Portugal, Investment company, ALPI, IBB, Mobile phone

The solution will utilize Multi-factor Authentication (MFA) access and Single Sign-on (SSO) to secure data access by all of ALPI Portugal’s internal users, including employees and third party drivers, as well as those with restricted access to their B2B website.

Key Points: 
  • The solution will utilize Multi-factor Authentication (MFA) access and Single Sign-on (SSO) to secure data access by all of ALPI Portugal’s internal users, including employees and third party drivers, as well as those with restricted access to their B2B website.
  • Additionally, ALPI aimed to enhance the user experience by integrating SSO (Single Sign-On) with web platforms, to ensure protected B2B interactions.
  • "We are proud to work with and enable secure authentication solutions for ALPI Portugal, an esteemed logistics provider.
  • This collaboration will allow us to jointly provide round-the-clock support for 24x7 operations like ALPI logistics," stated Alex Rocha, Managing Director at BIO-key EMEA.

Synthetic Biologics Expands Option for an Exclusive License Agreement with Massachusetts General Hospital

Retrieved on: 
Tuesday, August 3, 2021
Life sciences, Biotechnology, Health sciences, Hepatitis, Non-alcoholic fatty liver disease, Biopharmaceutical, Liver

Synthetic Biologics previously announced an option agreement with MGH to negotiate an exclusive license to IP and technology for the use of SYN-020 to prevent and treat metabolic and inflammatory diseases associated with aging.

Key Points: 
  • Synthetic Biologics previously announced an option agreement with MGH to negotiate an exclusive license to IP and technology for the use of SYN-020 to prevent and treat metabolic and inflammatory diseases associated with aging.
  • The option agreement has now been expanded to include technology developed by MGH to use SYN-020 to inhibit liver fibrosis in select diseases, including NAFLD.
  • Under the terms of the amended agreement, Synthetic Biologics is granted an option to negotiate an exclusive worldwide license with MGH to commercially develop SYN-020 to treat and prevent metabolic and inflammatory diseases associated with aging and fibrosis of the liver.
  • Synthetic Biologics recently announced the completion of patient dosing and observation of its Phase 1 single-ascending dose ("SAD") clinical trial of SYN-020 in 24 healthy adult volunteers.

Synthetic Biologics to Report 2020 Third Quarter Operational Highlights and Financial Results on November 10, 2020

Retrieved on: 
Tuesday, November 3, 2020
Life sciences, Anatomy, Health sciences, Biotechnology, Pharmaceutical industry, Pharmacy, Specialty drugs, Alkaline phosphatase, Gastrointestinal tract, ALPI, Biopharmaceutical

The dial-in information for the call is as follows:

Key Points: 
  • The dial-in information for the call is as follows:
    Participants are asked to dial in 15 minutes before the start of the call to register.
  • Synthetic Biologics, Inc. (NYSE American: SYN) is a clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need.
  • The Company is also advancing SYN-020, an oral formulation of the enzyme intestinal alkaline phosphatase (IAP) to treat both local GI and systemic diseases.
  • For more information, please visit Synthetic Biologics' website at www.syntheticbiologics.com .

Synthetic Biologics Announces FDA Clearance of Investigational New Drug Application for SYN-020 Intestinal Alkaline Phosphatase (IAP)

Retrieved on: 
Thursday, July 30, 2020
Life sciences, Natural sciences, Articles, Alkaline phosphatase, ALPI, Radiation therapy, Biopharmaceutical

If executed, the Company plans to use this license in the advancement of an expanded clinical development program for SYN-020.

Key Points: 
  • If executed, the Company plans to use this license in the advancement of an expanded clinical development program for SYN-020.
  • Synthetic Biologics has overcome this hurdle and has been able to produce SYN-020 at a scale and cost viable for clinical and commercial development.
  • Synthetic Biologics is currently developing SYN-020 to reduce acute intestinal side effects associated with radiation therapy in patients with pelvic cancers.
  • The Company is also advancing SYN-020, an oral formulation of the enzyme intestinal alkaline phosphatase (IAP) to treat both local GI and systemic diseases.

Synthetic Biologics to Report 2020 Second Quarter Operational Highlights and Financial Results on August 6, 2020

Retrieved on: 
Wednesday, July 29, 2020
Life sciences, Articles, Health, Biotechnology, Pharmaceutical industry, Pharmacy, Specialty drugs, Alkaline phosphatase, Gastrointestinal tract, ALPI, Biopharmaceutical, Microbiota

The dial-in information for the call is as follows:

Key Points: 
  • The dial-in information for the call is as follows:
    Participants are asked to dial in 15 minutes before the start of the call to register.
  • Synthetic Biologics, Inc. (NYSE American: SYN) is a clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need.
  • The Company is also advancing SYN-020, an oral formulation of the enzyme intestinal alkaline phosphatase (IAP) to treat both local GI and systemic diseases.
  • For more information, please visit Synthetic Biologics' website at www.syntheticbiologics.com .

Synthetic Biologics to Report 2020 First Quarter Operational Highlights and Financial Results on May 5, 2020

Retrieved on: 
Tuesday, April 28, 2020
Life sciences, Articles, Biotechnology, Pharmaceutical industry, Abdomen, Endocrine system, Gastrointestinal tract, Alkaline phosphatase, ALPI, Biopharmaceutical

The dial-in information for the call is as follows:

Key Points: 
  • The dial-in information for the call is as follows:
    Participants are asked to dial in 15 minutes before the start of the call to register.
  • Synthetic Biologics, Inc. (NYSE American: SYN) is a clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need.
  • The Company is also advancing SYN-020, an oral formulation of the enzyme intestinal alkaline phosphatase (IAP) to treat both local GI and systemic diseases.
  • For more information, please visit Synthetic Biologics' website at www.syntheticbiologics.com .

Synthetic Biologics to Report 2019 Third Quarter Operational Highlights and Financial Results on November 4, 2019

Retrieved on: 
Monday, October 28, 2019
Life sciences, Articles, Health, Digestive system, Abdomen, Endocrine system, Gastrointestinal tract, Alkaline phosphatase, ALPI, Biopharmaceutical

The dial-in information for the call is as follows:

Key Points: 
  • The dial-in information for the call is as follows:
    Participants are asked to dial in 15minutes before the start of the call to register.
  • Synthetic Biologics, Inc. (NYSE American: SYN) is a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need.
  • The Company is also advancing SYN-020, an early-stage oral formulation of the enzyme intestinal alkaline phosphatase (IAP) to treat both local GI and systemic diseases.
  • For more information, please visit Synthetic Biologics' website at www.syntheticbiologics.com .

Synthetic Biologics to Report 2019 Second Quarter Operational Highlights and Financial Results on August 8, 2019

Retrieved on: 
Thursday, August 1, 2019
Life sciences, Articles, Biotechnology, Pharmaceutical industry, Alkaline phosphatase, ALPI, Gastrointestinal tract, Biopharmaceutical

ET.

Key Points: 
  • ET.
  • The dial-in information for the call is as follows:
    Participants are asked to dial in 15minutes before the start of the call to register.
  • Synthetic Biologics, Inc. (NYSE American: SYN) is a clinical-stage company developing therapeutics that preserve the microbiome to protect and restore the health of patients.
  • The Companyis alsoadvancingSYN-020, anearly-stageoral formulation of the enzyme intestinal alkaline phosphatase (IAP) designed to treat both local GI and systemic diseases.For more information, please visit Synthetic Biologics' website at www.syntheticbiologics.com .